JAZZ PHARMACEUTICALS INC
Pharmaceutical therapeutics for neurological and oncological diseases
- Sector
- Biotech
- Headquarters
- PALO ALTO, CA
- Latest Form D
- $7M, Jul 2009
- Total capital
- $7M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $7M
- 1 Form D · last Jul 2009
- 208 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 17
- 23 pending · first 2013
- Rank in peer group#100 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#100 · top 7%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alan M. SebulskyDirectorNamed in SEC Form D filings
- Brian C. CresseyDirectorNamed in SEC Form D filings
- Bruce C. CozaddExecutive Officer, DirectorNamed in SEC Form D filings
- Bruce CozzadExecutive Officer, DirectorNamed in SEC Form D filings
- Bryan C. CresseyDirectorNamed in SEC Form D filings
- Carol A. GambleExecutive OfficerNamed in SEC Form D filings
Show all 18 people
- E. Alexander AlbertDirectorNamed in SEC Form D filings
- James C. MomtazeeDirectorNamed in SEC Form D filings
- James B. TananbaumDirectorNamed in SEC Form D filings
- Janne L.T. WisselExecutive OfficerNamed in SEC Form D filings
- Joan E. ColliganExecutive OfficerNamed in SEC Form D filings
- Kenneth W. O'KeefeDirectorNamed in SEC Form D filings
- Michael W. MichaelsonDirectorNamed in SEC Form D filings
- Michael W. MichelsonDirectorNamed in SEC Form D filings
- Nathaniel M. ZilkhaDirectorNamed in SEC Form D filings
- Patrick G. EnrightDirectorNamed in SEC Form D filings
- Robert M. MyersExecutive Officer, DirectorNamed in SEC Form D filings
- Samuel D. ColellaDirectorNamed in SEC Form D filings
What it has protected
USPTO · 17 granted of 40- GrantedDevices And Methods For Facilitating And Controlling Use Of A MedicationUSPTOUS 12,161,620
- GrantedSensitive Drug Distribution Systems And MethodsUSPTOUS 11,456,081
- PendingControlled Release Dosage Forms For High Dose, Water Soluble And Hygroscopic Drug SubstancesUSPTOApplication 17549151
Show all 40 patent records
- Devices And Methods For Facilitating And Controlling Use Of A MedicationDec 10, 2024 · US 12,161,620Granted
- Sensitive Drug Distribution Systems And MethodsSep 27, 2022 · US 11,456,081Granted
- Controlled Release Dosage Forms For High Dose, Water Soluble And Hygroscopic Drug SubstancesMar 31, 2022 · Application 17549151Pending
- Controlled Release Dosage Forms For High Dose, Water Soluble And Hygroscopic Drug SubstancesDec 28, 2021 · US 11,207,270Granted
- Sensitive Drug Distribution Systems And MethodsSep 23, 2021 · Application 16826909Pending
- Controlled Release Dosage Forms For High Dose, Water Soluble And Hygroscopic Drug SubstancesAug 17, 2021 · US 11,090,269Granted
- Devices And Methods For Facilitating And Controlling Use Of A MedicationJun 15, 2021 · US 11,033,530Granted
- Controlled Release Dosage Forms For High Dose, Water Soluble And Hygroscopic Drug SubstancesApr 27, 2021 · US 10,987,310Granted
- Controlled Release Dosage Forms For High Dose, Water Soluble And Hygroscopic Drug SubstancesApr 6, 2021 · US 10,966,931Granted
- Immediate Release Formulations And Dosage Forms Of Gamma-hydroxybutyrateApr 1, 2021 · Application 17067201Pending
- Controlled Release Dosage Forms For High Dose, Water Soluble And Hygroscopic Drug SubstancesMar 30, 2021 · US 10,959,956Granted
- Sensitive Drug Distribution Systems And MethodsJan 21, 2021 · Application 17061783Pending
- Controlled Release Dosage Forms For High Dose, Water Soluble And Hygroscopic Drug SubstancesOct 27, 2020 · US 10,813,885Granted
- Controlled Release Dosage Forms For High Dose, Water Soluble And Hygroscopic Drug SubstancesSep 1, 2020 · US 10,758,488Granted
- Microbiologically Sound And Stable Solutions Of Gamma-hydroxybutyrate Salt For The Treatment Of NarcolepsyOct 31, 2019 · Application 16382533Pending
- Immediate Release Formulations And Dosage Forms Of Gamma-hydroxybutyrateFeb 15, 2018 · Application 15791220Pending
- Devices And Methods For Facilitating And Controlling Use Of A MedicationOct 31, 2017 · US 9,801,852Granted
- Immediate Release Formulations And Dosage Forms Of Gamma-hydroxybutyrateOct 24, 2017 · US 9,795,567Granted
- Microbiologically Sound And Stable Solutions Of Gamma-hydroxybutyrate Salt For The Treatment Of NarcolepsyAug 10, 2017 · Application 15355599Pending
- Microbiologically Sound And Stable Solutions Of Gamma-hydroxybutyrate Salt For The Treatment Of NarcolepsyJan 10, 2017 · US 9,539,330Granted
- Sensitive Drug Distribution System And MethodJun 23, 2016 · Application 15057898Pending
- Sensitive Drug Distribution System And MethodJun 2, 2016 · Application 15014831Pending
- Microbiologically Sound And Stable Solutions Of Gamma-hydroxybutyrate Salt For The Treatment Of NarcolepsyMar 12, 2015 · Application 14250116Pending
- Microbiologically Sound And Stable Solutions Of Gamma-hydroxybutyrate Salt For The Treatment Of NarcolepsyFeb 10, 2015 · US 8,952,062Granted
- Microbiologically Sound And Stable Solutions Of Gamma-hydroxybutyrate Salt For The Treatment Of NarcolepsyOct 14, 2014 · US 8,859,619Granted
- Methods Of Administering Drugs In An Implantable Multi-chamber PumpOct 2, 2014 · Application 14228192Pending
- Sensitive Drug Distribution System And MethodJul 24, 2014 · Application 14219941Pending
- Sensitive Drug Distribution System And MethodJul 24, 2014 · Application 14219904Pending
- Method Of Administration Of Gamma Hydroxybutyrate With Monocarboxylate TransportersJul 8, 2014 · US 8,772,306Granted
- Sensitive Drug Distribution System And MethodJul 3, 2014 · Application 14196603Pending
- Gamma-hydroxybutyrate Compositions And Their Use For The Treatment Of DisordersNov 26, 2013 · US 8,591,922Granted
- Pharmaceutical Compositions Of Clonazepam And Methods Of Use ThereofApplication PCTUS2007018877Pending
- Defibrotide For The Prevention And Treatment Of Cytokine Release SyndromeApplication 62657161Pending
- Carbamoyl Phenylalaninol Analogs And Uses ThereofApplication PCTUS2018044465Pending
- Defibrotide For The Prevention And Treatment Of Cytokine Release Syndrome And Neurotoxicity Associated With ImmunodepletionApplication 62753711Pending
- Defibrotide For The Prevention And Treatment Of Cytokine Release Syndrome And Neurotoxicity Associated With ImmunodepletionApplication PCTUS2019027210Pending
- Gamma-hydroxybutyrate Compositions And Their Use For The Treatment Of DisordersApplication PCTUS2013074954Pending
- Gamma-hydroxybutyrate Compositions And Their Use For The Treatment Of DisordersApplication 61737695Pending
- Controlled Release Dosage Forms For High Dose, Water Soluble And Hygroscopic Drug SubstancesApplication PCTUS2011029802Pending
- Immediate Release Formulations And Dosage Forms Of Gamma-hydroxybutyrateApplication PCTUS2010033572Pending
Related companies, and why
- Cyprium Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Synoligo Biotechnologies, Inc.Similar federal contract value in Biotech · null in contracts
- Omnipulse Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- Vaneltix Pharma, Inc.Similar federal contract value in Biotech · null in contracts
- Secretome TherapeuticsSimilar federal contract value in Biotech · null in contracts
- BTB Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .